Developments in the Obesity Treatment Market

NEW YORK, March 16, 2018 /PRNewswire/ --

According to Grand View Research, the global obesity treatment market was valued at USD 3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. The demand for weight management continues to increase as obesity posts an enormous challenge to healthcare in developed countries as well as in lower and middle-income economies. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. In addition, increasing awareness of obesity's impacts on health further drives the growth of the market. The report indicated that the North American region holds the largest market share of global obesity treatment market due to growing overweight and obese population. BioCorRx Inc. BICX, Zafgen,Inc. ZFGN, ReShape Lifesciences Inc. RSLS, VIVUS, Inc. VVUS, ReShape Lifesciences Inc. RSLS, Obalon Therapeutics, Inc. OBLN

According to another report from Marketdata, the commercial weight loss programs segment of the obesity market is estimated to have grown 9.4 percent to $3.03 billion in 2017. John LaRosa, the Research Director of Marketdata, said: "The number of active dieters is estimated to have fallen 10% since 2015, to 97 million, due to a growing size acceptance movement and dieter fatigue. About 80% try to lose weight by themselves, but many fail and the latest CDC statistics show that we are getting fatter, not thinner. The new 2018 diet season is about to begin in late December, and the giants of the market are strongly positioned for more gains."

BioCorRx Inc. BICX yesterday announced, "an update on the pilot program for weight loss with Atlantis Medical Wellness & Weight Loss Center. The weight loss program began in October 2017 and the Company reports that Atlantis has successfully enrolled a total of twelve individuals to date as planned into the program. The initial results have been positive as reported by patients.

As mentioned in the Company's previous release, BioCorRx has teamed up with Dr. Benjamin Gonzalez, Medical Director of Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. Dr. Gonzalez is renowned for his expertise in clinical nutrition with a focus on exercise nutrition and weight management.

According to the CDC, more than one-third (36.5%) of U.S. adults have obesity. According to a 2012 article in the Journal of Health Economics, estimates of current healthcare costs of obesity range from $147 billion to nearly $210 billion per year. Some of the risks associated with this disease include heart disease and stroke, high blood pressure, metabolic syndrome, breathing problems and other health issues."

Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are very pleased with the feedback we have received from Dr. Gonzalez and the patients enrolled in the pilot program to date. We anticipated that this program would help individuals struggling with their weight in some way, but it's great to actually hear the excitement from those enrolled thus far. One of the first patients who enrolled in the program reported a weight loss of 25 pounds after three months along with healthier lifestyle habits. So far, most of the participants polled have expressed reduced cravings for food. We look forward to completing the pilot mid-year and plan to begin marketing the official weight loss program as anticipated immediately thereafter."

Zafgen,Inc. ZFGN is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. On January 5, 2018, the company announced strong clinical progress with its lead ZGN-1061 program currently in development for patients with complex type 2 diabetes. Additionally, the company unveiled plans to return to the rare metabolic disease space in 2018, with a second highly optimized MetAP2 development candidate, ZGN-1258, targeting an initial indication in Prader-Willi syndrome. ZGN-1258 is designed to change the way the body metabolizes fat, reduce fat mass and decrease hyperphagia in PWS, a rare genetic form of life-threatening obesity characterized by unrelenting pathologic hunger (hyperphagia) leading to dangerous food-seeking behavior.

ReShape Lifesciences Inc. RSLS is a medical device company focused on technologies to treat obesity and metabolic diseases. Recently, the company announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc™ products to U.S. Department of Defense (DoD) medical facilities. Through this agreement, the ReShape Balloon and ReShape vBloc are both now approved products for sale into DoD medical facilities. This new agreement adds increased distribution by Academy Medical of ReShape vBloc, which has been distributed through Academy Medical to VA facilities since May 2016. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and DoD hospitals and community-based outpatient clinics.

VIVUS, Inc. VVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. The company's products are indicated for the treatment of obese and overweight patients and for erectile dysfunction. Erectile dysfunction can lead to reduced quality of life for the millions of men living with the condition. Recently, the company reported financial results for the quarter and year ended December 31, 2017 and provided a business update. Total revenue, net for the fourth quarters of 2017 and 2016, was $11.9 million and $81.8 million, respectively. Approximately 91,000 and 100,000 Qsymia prescriptions were dispensed in the fourth quarters of 2017 and 2016, respectively. Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Obalon Therapeutics, Inc. OBLN is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. On March 05, 2018, the company announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017. The Company reported total revenue of $3.7 million for the fourth quarter of 2017, compared to $0.8 million for the fourth quarter of 2016. U.S. revenue of $2.9 million represented 78% of total revenue and international revenue of $0.8 million represented 22% of total revenue for the fourth quarter 2017.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has not been compensated by any companies mentioned. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .

For further information:
Media Contact: info@financialbuzz.com
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com